You are here

Article Text

Article menu
Download PDFPDF
Letter
Conflicting advice
  1. A Finn,
  2. R Booy,
  3. M Sharland,
  4. P Heath
  1. University of Bristol, Bristol, UK
  1. Correspondence to Professor Finn;
    adam.finn{at}bristol.ac.uk

https://doi.org/10.1136/adc.88.2.176

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Concerning use of conjugate pneumococcal vaccine, the most recent CMO letter1 sent out in August 2002, updates the recommendations issued by the Department of Health (DoH) in January 20022 by making the recommendations for “at risk” under 2 year old children coincide with the manufacturer’s recommendations for immunisation of normal healthy children in their Summary of Product Characteristics for their European product licence.

    These schedules differ a little bit from those set out in our paper3 which was subsequently cited in the recent RCPCH guidelines for immunisation of immunocompromised …

    View Full Text